IP Library › Granted Patent US 12,595,252
Granted Patent B2
US 12,595,252 · App. 17/615,907 · Granted Apr 7, 2026

Inhibitors of SARM1

Inventors: Robert Owen Hughes (Newtown, CT); Rajesh Devraj (Chesterfield, MO); Todd Bosanac (New Milford, CT); Richard Andrew Jarjes-Pike (Newbury, GB); Andrew Simon Brearley (Chilton, GB); Jonathan Bentley (Abindgon, GB); Shelley Anne Parrott (Abindgon, GB); Sophie Catherine Cooper (Abindgon, GB)
Assignee: DISARM THERAPEUTICS, INC.
C07D403/12C07D241/18C07D401/12C07D401/14C07D405/12C07D405/14C07D413/12C07D471/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,595,252
App. No.
17/615,907
Granted
Apr 7, 2026
Kind
B2
Abstract

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Claims (5)

1 . A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2 . A method comprising a step of: administering a compound of claim 1 to a subject who (i) has a condition characterized by axonal degeneration or (ii) is at risk of developing a condition characterized by axonal degeneration.

3 . A method of treating or preventing axonal degeneration comprising administering to a subject in need thereof a compound of claim 1 .

4 . A method of inhibiting SARM1 comprising contacting a biological sample with a compound of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: JARJES-PIKE, RICHARD ANDREW; BREARLEY, ANDREW SIMON; BENTLEY, JONATHAN; PARROTT, SHELLEY ANNE; COOPER, SOPHIE CATHERINE
To: EVOTEC (UK) LTD
Reel/Frame 058267/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: EVOTEC (UK) LTD
To: EVOTEC INTERNATIONAL GMBH
Reel/Frame 058267/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: HUGHES, ROBERT OWEN; DEVRAJ, RAJESH; BOSANAC, TODD; EVOTEC INTERNATIONAL GMBH
To: DISARM THERAPEUTICS, INC.
Reel/Frame 058268/0018 →
Continuity (2)
Provisional Application 62861501 · Jun 14, 2019
Related Publication 20220340546A1 · Oct 27, 2022
References Cited (40)
US 9486521B2 · Freeman et al. · 2016 [cited by applicant]
US 11903935B2 · Milbrandt · 2024 [cited by examiner]
US 12083114B2 · Bosanac · 2024 [cited by examiner]
US 20120328629A1 · Freeman et al. · 2012 [cited by applicant]
US 20150011575A1 · Walter et al. · 2015 [cited by applicant]
EP 1050531A1 · 2004 [cited by applicant]
WO WO0160806A2 · 2001 [cited by examiner]
WO 2012178022A2 · 2012 [cited by applicant]
WO 2018035204A1 · 2018 [cited by applicant]
WO 2018057989A1 · 2018 [cited by applicant]
WO 2019236879A1 · 2019 [cited by applicant]
WO 2019236884A1 · 2019 [cited by applicant]
WO 2019236890A1 · 2019 [cited by applicant]
WO 2020081923A1 · 2020 [cited by applicant]
WO 2020132045A1 · 2020 [cited by applicant]
WO 2020247701A2 · 2020 [cited by applicant]
Roe et al., The Preparation of Heterocyclic Fluorine Compounds by the Schiemann Reaction.I. The Monofluoropyridines, 1947, Journal of the American Chemical Society, 69, pp. 2443-2444 (Year: 1947). [cited by examiner]
Ukrorgsyntez Ltd., RN 1866712-36-8, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1878025-49-0, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1878025-71-8, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1879279-46-5, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1880323-60-3, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1881619-70-0, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 2025746-70-5, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1874857-24-5, 2016, CAPLUS (Year: 2016). [cited by examiner]
Enamine, RN 1424456-86-9, 2013, CAPLUS (Year: 2013). [cited by examiner]
Ukrorgsyntez Ltd., RN 1694743-67-3, 2015, CAPLUS (Year: 2015). [cited by examiner]
RN 6905-47-1, 1984, CAPLUS (Year: 1984). [cited by examiner]
Aurora Fine Chemicals, RN 1516709-09-3, 2014, CAPLUS (Year: 2014). [cited by examiner]
Enamine, RN 1428041-01-3, 2013, CAPLUS (Year: 2013). [cited by examiner]
Aurora Fine Chemicals, RN 1493229-84-7, 2013, CAPLUS (Year: 2013). [cited by examiner]
Aurora Fine Chemicals, RN 1502513-50-9, 2013, CAPLUS (Year: 2013). [cited by examiner]
Aurora Fine Chemicals, RN 1517681-35-4, 2014, CAPLUS (Year: 2014). [cited by examiner]
Ukrorgsyntez Ltd., RN 1851689-39-8, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1874934-02-7, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1875035-51-0, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1875592-76-9, 2016, CAPLUS (Year: 2016). [cited by examiner]
Ukrorgsyntez Ltd., RN 1876454-45-3, 2016, CAPLUS (Year: 2016). [cited by examiner]
Gerdts et al., “Axon self destruction: new links among SARM1, MAPKs, and NAD+ metabolism,” Neuron, 2016, vol. 39(3), pp. 449-460. [cited by applicant]
Lawrence et al., “Development of ortho-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors,” J Med Chem., 2012, vol. 55(17), pp. 7392-7416. [cited by applicant]